New COVID-19 vaccine shows promise in early trial
NCT ID NCT04639466
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This study tested a new COVID-19 vaccine called GEO-CM04S1 in 119 healthy adults. The goal was to check its safety and find the best dose to trigger a strong immune response. The vaccine uses a modified virus to teach the body to fight SARS-CoV-2, the virus that causes COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
EmVenio Research
Claremont, California, 91711, United States
-
Millennium Clinical Trials
Thousand Oaks, California, 91360, United States
Conditions
Explore the condition pages connected to this study.